Core Viewpoint - Four Seasons Pharmaceutical (0460.HK) experienced a significant intraday increase of over 10%, reaching a peak of 1.58 HKD, marking the highest level since February 2022 [1] Group 1: Company Developments - The company announced that its non-wholly owned subsidiary, Huisheng Biopharmaceutical Co., Ltd., has received acceptance for the market application of Semaglutide injection from the National Medical Products Administration (NMPA) for improving blood sugar control in adult patients with type 2 diabetes [1] - The clinical trial for Semaglutide injection's indication for weight loss has completed Phase III enrollment and is currently in the follow-up stage [1] Group 2: Competitive Position - Huisheng Biopharmaceutical is noted as the only biopharmaceutical company in China with a comprehensive product coverage in the diabetes and complications field, which enhances its competitive edge [1] - The company has nearly 20 approved diabetes and complications drugs in its product portfolio, and the richness of its research pipeline provides solid support for its long-term development [1]
港股异动｜四环医药涨超10%创近三年半新高 附属公司司美格鲁肽注射液上市申请获药监局受理